Hepatitis B News and Research

Latest Hepatitis B News and Research

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

GI Society releases video to spread awareness about hepatitis C

As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease.

10 Feb 2015

BPC opens new plasma collection center in Jacksonville, North Carolina

Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, is pleased to announce that it has opened a new plasma collection center. The state-of-the-art, 15,000 square foot facility located at 113 Yopp Road, Jacksonville, North Carolina, is BPC's second plasma center in Jacksonville, and officially opened its doors for business on February 3, 2015.

9 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others.

9 Feb 2015

HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

More than 180 million people in the world have hepatitis C, compared with the 34 million with HIV/AIDS and the roughly 30,000 who have had Ebola.

9 Feb 2015

40% of prison and jail inmates have chronic medical problems, shows BJS survey

An estimated 40 percent of state and federal prisoners and jail inmates reported having a current chronic medical condition in the 2011–12 National Inmate Survey, the Bureau of Justice Statistics (BJS) announced today.

6 Feb 2015

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children.

6 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

MIT engineers discover way to grow liver-like cells to test potential malaria drugs

In 2008, the World Health Organization announced a global effort to eradicate malaria, which kills about 800,000 people every year. As part of that goal, scientists are trying to develop new drugs that target the malaria parasite during the stage when it infects the human liver, which is crucial because some strains of malaria can lie dormant in the liver for several years before flaring up.

6 Feb 2015

Howard K. Koh receives CADCA's 2015 National Leadership Award

In recognition of his significant contributions to public health and tobacco prevention, and his long-standing support of community-based drug prevention, Community Anti-Drug Coalitions of America (CADCA) will present Howard K. Koh M.D., M.P.H. with its 2015 National Leadership Award.

5 Feb 2015

Researchers suggest novel concept for developing vaccines against HIV and cancer

A experimental trial has shown successful by inducing serum in mice and has been highly neutralizing towards those ailments.

4 Feb 2015

Trust for America's Health supports President's proposal to end sequestration

The following is a statement from Jeffrey Levi, PhD, executive director of the Trust for America's Health (TFAH) and chair of the Advisory Group on Prevention, Health Promotion, and Integrative and Public Health.

4 Feb 2015

International community funding can significantly reduce cancer deaths in LMICs by 2030

Increased annual international community funding of US$18 billion globally could save three million lives per year by 2030 and many more in succeeding decades,

3 Feb 2015

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer.

2 Feb 2015

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464.

2 Feb 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

With President Obama's recent State of the Union speech addressing the launch of a national precision medicine initiative to further tackle cancer and other diseases, a leading immunotherapy expert from Rutgers Cancer Institute of New Jersey weighs in on where we stand with precision immunology and personalized medicine and what needs to be accomplished.

30 Jan 2015

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest’s national testing database.

From Quest Diagnostics 29 Jan 2015

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report.

28 Jan 2015

Hepatitis B News and Research

Latest Hepatitis B News and Research

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

GI Society releases video to spread awareness about hepatitis C

BPC opens new plasma collection center in Jacksonville, North Carolina

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

New AGA guideline provides guidance to prevent HBV reactivation

HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

40% of prison and jail inmates have chronic medical problems, shows BJS survey

Researchers develop new MRI-based technique to better detect NAFLD in children

Chemotherapy or immunosuppressive treatment may reactivate HBV

MIT engineers discover way to grow liver-like cells to test potential malaria drugs

Howard K. Koh receives CADCA's 2015 National Leadership Award

Researchers suggest novel concept for developing vaccines against HIV and cancer

Trust for America's Health supports President's proposal to end sequestration

International community funding can significantly reduce cancer deaths in LMICs by 2030

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis B News and Research

Latest Hepatitis B News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in